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ABSTRACT 
Facilities that provide cancer care are increasingly promoting their services directly to the public 
through advertisements.  In the past few years, cancer center advertising has received criticism 
for making unsupported claims about survival, omitting risk information, and using emotional 
language. Although there is a large body of evidence regarding the content, impact, and 
regulation of pharmaceutical advertising, there is little known about that of cancer centers. This 
study aimed to assess the evidence regarding advertising by facilities that provide cancer care.  
The author conducted a rapid review of publications that analyzed the content of cancer center 
advertising published before February 15, 2013.  Only two peer-reviewed studies were selected 
for inclusion from 353 publications identified by the review.  Both were cross-sectional studies 
and reported the use of emotional appeal and patient testimonials as advertising strategies. While 
the number of studies found was too small and their methods and quality too variable to allow 
for any confident conclusions to be made, this study identified a considerable gap in the 
literature. Descriptive studies of the content of cancer center advertising are needed to move the 
debate forward and inform studies measuring the impact on the public.  Understanding the 
messages conveyed through cancer center advertisements and their effect on the population are 
of high public health importance, as such messages have the potential to affect health costs, 
patient preferences and expectations about treatment, and the provider-patient relationship.   
Thomas Guadamuz, PhD 
WHAT ARE CANCER CENTERS ADVERTISING TO THE PUBLIC? 
A RAPID REVIEW OF THE LITERATURE 
Laura Borgenheimer, MPH 
University of Pittsburgh, 2013
 
v 
TABLE OF CONTENTS 
1.1 RESEARCH QUESTION AND OBJECTIVES ............................................... 3 
2.0 BACKGROUND .......................................................................................................... 5 
2.1 RECENT TRENDS IN DIRECT-TO-CONSUMER ADVERTISING .......... 5 
2.1.1 Evolution of Patient Decision-Making Preferences ...................................... 5 
2.1.2 Technology Innovations and Access to Information .................................... 6 
2.1.3 Federal Regulations ......................................................................................... 7 
2.2 CURRENT LITERATURE ON CANCER-RELATED DTCA ...................... 9 
2.2.1 Pharmaceutical DTCA .................................................................................... 9 
2.2.1.1 Content of Pharmaceutical DTCA ...................................................... 9 
2.2.1.2 Patient and Provider Perspectives and Impact On Behavior ......... 10 
2.2.1.3 Cost-Effectiveness and Appropriateness of Prescription ................ 13 
2.2.2 DTCA of Cancer Prevention Services ......................................................... 13 
2.2.3 Genetic Testing .............................................................................................. 14 
2.2.4 Cancer Screening Services ............................................................................ 16 
2.3 ADVERTISING BY CANCER CENTERS..................................................... 17 
3.0 METHODS ................................................................................................................. 23 
3.1 SELECTION CRITERIA ................................................................................. 23 
3.2 SEARCH STRATEGY ...................................................................................... 23 
1.0 INTRODUCTION .................................................................................................................. 1
vi 
3.3 DATA EXTRACTION ...................................................................................... 25 
4.0 RESULTS ................................................................................................................... 26 
4.1 STUDY SELECTION ....................................................................................... 26 
4.2 CHARACTERISTICS OF STUDIES INCLUDED ....................................... 28 
4.3 STUDY OUTCOMES ....................................................................................... 30 
4.4 STUDY QUALITY ............................................................................................ 33 
5.0 DISCUSSION ............................................................................................................. 34 
5.1 SYTHESIS AND LIMITATIONS OF RESULTS .......................................... 34 
5.2 COMMONALITIES BETWEEN STUDIES .................................................. 35 
5.2.1 Institutional Prestige ..................................................................................... 36 
5.2.2 Emotional Appeal .......................................................................................... 36 
5.2.3 Patient Testimonials ...................................................................................... 37 
5.3 COMMUNICATION THEORIES................................................................... 39 
5.3.1 Expectancy-Value Theories .......................................................................... 39 
5.3.2 Media-Effect Theories ................................................................................... 40 
5.4 RESEARCH PRIORITIES............................................................................... 41 
6.0 CONCLUSION ........................................................................................................... 43 
6.1 STUDY LIMITATIONS ................................................................................... 43 
6.2 PUBLIC HEALTH RELEVANCE .................................................................. 44 
6.3 FINAL REMARKS ........................................................................................... 45 
APPENDIX A: KANTAR LICENSE AGREEMENT.............................................................. 46 
APPENDIX B: EMAIL CORRESPONDENCE WITH KANTAR MEDIC 
REPRESENTATIVE.................................................................................................................. 53 
BIBLIOGRAPHY ...................................................................................................................... 61 
vii 
 LIST OF TABLES 
Table 1.  Characteristics and Main Findings of Studies that Fulfilled Search Criteria ................ 29 
viii
LIST OF FIGURES 
Figure 1.  Examples of Advertisements Placed By Cancer Centers in 2012, Obtained from Kantar 
Media ............................................................................................................................................ 21 
Figure 2.  Literature Search and Article Selection ........................................................................ 27 
1 
1.0     INTRODUCTION 
Communication of health-related messages through the media has captured the attention of 
health professionals due to its power to influence human behavior (C. F. Parvanta, 2011).  In 
public health, much funding is allocated to social marketing, the application of marketing 
techniques to increase the acceptability of an idea, practice, or product to enhance health (S. A. 
Parvanta & Parvanta, 2011).  By informing and persuading the public when health practices and 
products have proven health benefits and scientific consensus, public-health efforts have 
advanced (C. F. Parvanta, 2011).  
While social-marketing messages offer clear public-health benefit, the value of other 
health-product promotional efforts—such as the marketing of health care services—is less 
certain.  Proponents argue that such advertising educates the public about health services and 
treatment options and empowers consumers to take an active role in their medical decision-
making (Kravitz & Bell, 2007). In contrast, opponents argue that persuasion is the only aim of 
such ads; in fact, they have found the educational value of such advertisements questionable, and 
have noted that ads can negatively affect the patient-provider relationship. (Abel et al., 2012; 
Frosch, Grande, Tarn, & Kravitz, 2010; Kravitz, 2000).  
Companies that promote health products and services utilize various marketing models 
(Abel et al., 2012).  One that has received considerable attention is direct-to-consumer 
advertising (DTCA).  This marketing effort delivers unsolicited information about medication or 
services to the public in popular media (Wilkes, Bell, & Kravitz, 2000).  In the DTCA model, 
access to a product or service requires permission by a health care provider, whereas in other 
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models these goods can be purchased directly by consumers without approval from a gatekeeper 
(S. W. Gray & Abel, 2012).  DTCA includes broadcast (television and radio) and print 
(newspaper and magazine) advertisements, billboards, and direct mailings (Wilkes et al., 2000).  
This form of advertising does not include solicited information, such as information requested 
about a pharmaceutical drug (Abel et al., 2006).  
Within the realm of cancer, advertisements for oncology-related pharmaceutical 
medications, genetic testing for cancer mutations, and imaging services for cancer screening are 
clear examples of direct-to-consumer advertising (Abel et al., 2012).  It is also important to 
recognize that with increased competition for healthcare expenditures, facilities that provide 
cancer care—such as hospitals, clinics, and cancer centers—advertise heavily to increase 
revenue (S. W. Gray & Abel, 2012).  U.S. hospitals spend billions of dollars in advertising each 
year, and spending continues to rise (Newman Andrew Adam, 2011).   
Advertisements from both non-profit and for-profit cancer centers have raised concerns 
among health professionals due to the unsubstantiated claims about survival, the use of 
emotional language, the promotion of innovative therapies, and the use of testimonials from 
atypical patients (Abel et al., 2006; Kravitz & Bell, 2007; Oxman, January, 2007).  Critics have 
noted that patients who view such ads may come away with unrealistic expectations about 
treatment benefit, which may influence their treatment decisions (Weeks et al., 1998). 
Additionally, claims about survival have raised concerns that ads may prompt patients to travel 
across the country for treatment that is likely available closer to home, which may increase total 
costs for care (Singer, December 18, 2009). Lastly, some believe that the use of emotional 
language may be inappropriate for cancer patients already experiencing fear, uncertainty, and 
anxiety (Singer, December 18, 2009).   
3 
1.1 RESEARCH QUESTION AND OBJECTIVES 
Despite these concerns, there has been little examination of the content of cancer center ads, and 
to date no review has been conducted to examine or synthesize such analyses.  As such, this 
study aimed to rapidly review the literature for content analyses characterizing direct-to-
consumer advertisements by cancer centers that included information about the types of services 
and treatments advertised the balance of language about benefits and risks of treatments, and the 
use of language about emotion, survival, and innovation.  The major questions were:  1) What 
evidence exists in the peer-reviewed literature about the content of direct-to-consumer 
advertising by cancer centers? 2) What is the level of evidence, as measured by the number of 
studies and research design? and 3) Where are the gaps in evidence, and what future work is 
needed? 
The second chapter of this paper will discuss the rise in direct-to-consumer advertising 
and discuss reasons for this increase, including the evolution of patient decision-making 
preferences, technology innovations and widespread access to information, and changes in 
regulations at the federal level.  The author will discuss what is known about the content and 
impact of different forms of cancer-related DTCA, including pharmaceutical, genetic testing, and 
cancer screening services.  The second chapter will also present what is known about cancer 
center advertising, and why a review is necessary. 
The third chapter describes the selection criteria, search strategy, and data extraction 
process of the rapid review.   In the fourth chapter, the author presents the results of the review, 
giving particular attention to the study selection, the characteristics and outcomes of the studies 
selected, and the quality of studies.  The fifth chapter provides a synthesis and critique of the 
results and critique the studies, including the commonalties and differences between study design 
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and outcomes, integrate relevant theories, and provide recommendations for future research.  The 
sixth chapter presents the limitations of this paper and offers final remarks. 
5 
2.0  BACKGROUND 
2.1 RECENT TRENDS IN DIRECT-TO-CONSUMER ADVERTISING 
Real spending on health-related DTCA has increased dramatically over the last decade and a 
half, with a rise of 330% between 1996 and 2007 (J. M. Donohue, Cevasco, & Rosenthal, 2007).  
In 1990, $47 million was spent on print and broadcast advertising.  By 2000, this amount had 
grown to more than $2.5 billion (Fintor, 2002), and in 2005 increased to over $4 billion (J. M. 
Donohue et al., 2007).  Multiple factors have influenced this rising trend, including an evolution 
of patient decision-making preferences and information seeking behaviors (Frosch & Kaplan, 
1999), technology innovations and widespread access to cancer information through television, 
the Internet, and mobile devices (Viswanath, 2005), and changes in advertising regulations at the 
federal level, making it more cost-effective for companies to advertise medications and services 
in lay media (Fintor, 2002; Kravitz, 2000). 
2.1.1 Evolution of Patient Decision-Making Preferences 
Today, more so than ever, patients are encouraged to take an active role in making decisions 
about their medical care (Frosch et al., 2010). In the past few decades, there has been a paradigm 
shift from a paternalistic model of care, in which the health care provider makes the decisions 
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and the patient has a low-level of involvement, to a shared model of care where patients are 
actively engaged in their medical decisions (Frosch & Kaplan, 1999; Kaplan & Frosch, 2005).   
Numerous studies have shown that cancer patients actively seek information about their 
diagnosis and treatment options from the Internet, newspapers, and magazines (Butow, Maclean, 
Dunn, Tattersall, & Boyer, 1997; Kelly et al., 2010; Nagler et al., 2010).  This information 
sought by patients is associated with patient behaviors and influences their preferences for 
treatment, including the use of targeted therapies (S. W. Gray, Armstrong, Demichele, Schwartz, 
& Hornik, 2009; C. J. Lee, Gray, & Lewis, 2010).  Direct-to-consumer advertising has increased 
as patients seek information on medical choices, and advertisements provide patients with new 
information about medications and services, as well as their indications, benefits, and risks.  
Proponents of DTCA have claimed that advertisements educate and empower patients with new 
information, creating a more informed and assertive population (Bonaccorso & Sturchio, 2002; 
Kravitz & Bell, 2007).  Research has shown that advertising increases consumers’ awareness of 
the product promoted and also influences their preferences for such treatment (Fintor, 2002).   
2.1.2 Technology Innovations and Access to Information 
The evolution of patient preferences for decision making and information-seeking behaviors 
have been possible due to technology innovations that make information widely accessible and 
instantaneous, namely through computers and mobile devices (Basch, Thaler, Shi, Yakren, & 
Schrag, 2004; Viswanath, 2005).  The amount of information on cancer on the Internet continues 
to proliferate, with millions of hits generated from a single search on cancer (Viswanath, 2005).  
This increase in access to information allows for the easy and rapid delivery of cancer 
information to the public, including information on disease prevention, management and 
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treatment and coping strategies and support.  With this increase in information availability has 
come an increase in advertising; companies can promote their services through online banner ads 
on cancer educational websites, create websites for rapid dispersal of information, , and produce 
television commercials that air on popular networks or online.  This digitization of information 
has created unlimited opportunities for health-related advertising.  
2.1.3 Federal Regulations 
Changes in health-care advertising regulations at the federal level have influenced the rapid 
growth of health-services advertising in the United States (Bell, Kravitz, & Wilkes, 2000).  Two 
governmental agencies regulate advertising at the federal level in the United States:  the U.S. 
Food and Drug Administration (FDA) and the U.S. Federal Trade Commission (FTC).  With the 
passage of the Food Drug, and Cosmetic Act in 1938, the FDA was given authority to control 
labeling for both over-the-counter and prescription drugs, but regulation of advertising remained 
with the FTC (Kravitz, 2000).  The Kefauver-Harris amendments of 1962, with goals of 
increasing patient safety and protection, gave the FDA full jurisdiction over prescription drugs 
and medical devices advertising.  Regulations required ads to provide information about side 
effects, drug indications and effectiveness, as well as “fair balance,” or a summary of risks and 
benefits of the medication or device. Guidelines also required that text size and ease of 
comprehension of risk information be equal to that of benefit information (Food and Drug 
Administration, 2009).  
With preferences for medical decision-making throughout the 60s and 70s being 
paternalistic in nature, manufacturers promoted their pharmaceutical drugs and medical devices 
to health care providers.  The idea of marketing directly to consumers was “inconceivable” 
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(Kravitz, 2000).  However, the evolution in patient decision-making preferences shifted the 
pharmaceutical industry’s perspective on advertising to the public in 1981.  The industry argued 
(in its proposal to the FDA) that the educational benefit of direct-to-consumer advertising would 
empower the public to be active, informed participants in medical decision making (Kravitz, 
2000).  The FDA studied the proposal and approved it in 1985, allowing pharmaceutical 
companies to advertise directly to the public, provided they abide by existing standards.  The 
industry was not satisfied, however, and argued that the mandate to provide a brief summary (of 
side effects, effectiveness, and contraindications) was burdensome and provided no additional 
value to consumers (Kontos & Viswanath, 2011).   
In 1997 the FDA created new guidelines for broadcast advertising and no longer required 
the disclosure of all risks and side effects to be presented in the advertisement (Kontos & 
Viswanath, 2011), provided the manufacturer issued an inclusive statement about risks available 
from another source, such as a toll-free telephone number, concurrent print ad, physician or 
Internet address (Kravitz, 2000). This regulatory change made it easier to advertise through 
broadcast media and brought forth an eruption of television and radio advertisements in 1997 
(Fintor, 2002).  Although DTCA campaigns were (and are) advertised through several media 
outlets, including magazines, newspapers, television, and radio, this regulation change shifted the 
majority of DTCA spending from print to broadcast media (J. Donohue, 2006; J. M. Donohue et 
al., 2007; Fintor, 2002).  
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2.2 CURRENT LITERATURE ON CANCER-RELATED DTCA 
2.2.1 Pharmaceutical DTCA 
Much of the increase in DTCA is due to the promotion of pharmaceutical drugs (Fintor, 2002).  
Most advertisements for pharmaceutical medications are product-specific, i.e. mention a drug by 
name and describe its indication for use, safety, and effectiveness (Kravitz, 2000).  Cancer-
related medications have been advertised to consumers since the liberalization of FDA 
regulations in 1997, mainly through magazines and television (Kontos & Viswanath, 2011). 
Figure 1 highlights two examples of DTCA of cancer-related prescription drugs that appeared in 
consumer magazines. A considerable amount of research has examined the content of these types 
of product-specific ads, which has informed the policy debate (Abel, Lee, & Weeks, 2007; S. W. 
Gray & Abel, 2012; Kontos & Viswanath, 2011). 
2.2.1.1 Content of Pharmaceutical DTCA 
Multiple content analyses have examined pharmaceutical DTCA, showing that although the FDA 
requires a “fair balance” of risk and benefit language, companies often overemphasize benefit 
information (Abel et al., 2007; Bell, Kravitz, et al., 2000; Bell, Wilkes, & Kravitz, 2000).  One 
study examined the content of product-specific DTC pharmaceutical ads in popular magazines, 
and found that forty percent of ads mentioned risks last (Bell, Kravitz, et al., 2000). The study 
reported the dramatic rise of new brand appearances: in 1989 there were fewer than five, and by 
1998 this increased to eighteen. The most common conditions targeted were allergies (46 ads), 
obstetrical/gynecological (45 ads), dermatological (37 ads), and cardiovascular (36 ads).  Cancer 
was the condition targeted the least, with only two drugs advertised, Eulexin and Nolvadex.  
  10 
Another concerning finding about DTCA of pharmaceutical medications is the difficulty 
of the public to fully comprehend the information.  While social marketers are experts at 
tailoring communication messages so that the public can easily understand, this does occur with 
DTCA.  Early research on DTCA for pharmaceuticals showed that consumers did not have the 
clinical or pharmaceutical background to fully understand and evaluate pharmacological 
advertisements (Cohen, 1988).  Subsequent analyses have supported this conclusion, suggesting 
this information is difficult to read and requires a higher level of literacy than most consumers 
have (Kaphingst, Rudd, DeJong, & Daltroy, 2004, 2005).  
The content analyses of cancer-related pharmaceutical DTCA have shown that, although 
the information is difficult to understand, the risks and benefits information presented equally, 
and cancer patients usually find advertisement information helpful (Abel, Burstein, Hevelone, & 
Weeks, 2009; Abel et al., 2007; Abel et al., 2006).  A content analysis conducted during a three 
and a half year period examined 284 unique advertisements from 49 different campaigns and 
found that ads frequently promoted medication effectiveness and made references to clinical data 
(Abel et al., 2007).  Most ads gave equal amount of text to risks and benefits information, but 
texts were usually difficult to read (i.e., were at a college reading level), as indicated by a 
standard measure of text readability.   
2.2.1.2 Patient and Provider Perspectives and Impact On Behavior  
While the content of DTCA is important for understanding what is being promoted, it is equally 
important to understand how this type of advertising influences consumer behavior and the 
patient-provider relationship. To understand opinions of DTCA for pharmaceutical medication, 
the FDA conducted a survey in 1999 of 1,081 consumers and found that 52% of respondents 
reported they “like” seeing advertisements (Aiken K, Swassy J, & Braman A, 2002).  The same 
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survey was repeated in 2002 among 960 consumers and 500 physicians (Aiken K et al., 2002).  
The number of participants who said they “like” seeing ads had declined to 32% in 2002.  In 
1999, only 18% of respondents turned to the Internet for more information, whereas in 2002, 
38% did so.  Forty percent of physicians thought DTCA was positive, 32% thought it was 
negative, and 28% thought it had no overall effect. This survey is often cited as evidence that 
health providers do not feel that DTCA should be eliminated, despite the findings of other 
studies (Abel et al., 2006).  
Other surveys have reported both negative and positive attitudes toward DTCA (Murray, 
Lo, Pollack, Donelan, & Lee, 2004; Robinson et al., 2004).  A large survey of 3,000 respondents 
found that 86% of adult consumers were aware of DTCA, and among those, 36% discussed the 
advertised medication with their physician (Weissman et al., 2003a).  A separate national survey 
found that, among 643 physicians, 70% felt that DTCA helped to educate patients (Weissman et 
al., 2003b).  Physicians reported prescribing a medication approximately 39% of the time it was 
requested.  
One survey found that patients with cancer were highly aware of cancer-related DTCA, 
but that there were minimal changes in providers’ choice of prescription medication (Abel et al., 
2009).  Of 348 respondents, 86.2% reported being aware of cancer-related direct-to-consumer 
advertising. Patients were more frequently aware of DTCA on television (77.7%) and in 
magazines (66.7%).  Among those aware of DTCA, a majority (62%) reported that the 
advertisements made them more aware of treatments they did not know about, and 57% reported 
it helped them have better discussions with their physicians.  Only 17% reported talking to their 
provider about a specific advertised medication, and less than one-fifth of those patients received 
a prescription for the medication. The investigators discovered that these positive aspects of 
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DTCA came at a price:  11% of patients reported that DTCA made them less confident in their 
providers’ judgment, a “potentially devastating effect for the patient-provider relationship” (S. 
W. Gray & Abel, 2012).  
Studies to assess providers’ attitudes towards oncology-related pharmaceutical 
advertising are less common, but are available.  In one such study, investigators surveyed 221 
oncology nurse practitioners (Viale & Sanchez Yamamoto, 2004).  Results showed that 
discussion about pharmaceutical advertisements were common in provider-patient discussions.  
Ninety-four percent of providers had received a patient request for a medication due to an 
advertisement, and 40% received one to five medication requests each week. Seventy-four 
percent of providers reported that patients ask for inappropriate medications, and 43% sometimes 
felt pressured to prescribe the medication requested.   
Interestingly, primary care physicians view DTCA more negatively than specialists 
(Aiken K et al., 2002), and they are less receptive to questions and medication requests when 
they arise from DTC advertisements (Zachry, Dalen, & Jackson, 2003).  General providers in 
particular face increasing pressure to see more patients in less time, with the average clinical visit 
being around fifteen minutes (Fiscella & Epstein, 2008).  Discussing information a patient 
learned from an advertisement takes valuable time, especially if the ad was misleading and did 
not provide enough information about indications, risks, or alternate treatments (Lipsky & 
Taylor, 1997).  While communication is essential to the patient-provider relationship, and 
providers should take time to communicate medication risks and benefits, dialogue resulting 
from advertisements should not impede the delivery of other essential information in the clinical 
encounter.  In addition, providers must deliver the bad news that ads often omit, such as 
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insurance coverage information; this in turn may decrease patient satisfaction with their 
providers (Abel et al., 2006). 
2.2.1.3  Cost-Effectiveness and Appropriateness of Prescription  
While oncology-specific studies are rare, a recent study on the cost-effectiveness of general 
pharmaceutical DTCA reported that such advertising leads to an increased demand for 
medications, but that it may also lead to inappropriate prescriptions (Atherly & Rubin, 2009).  
Whereas drugs that are proven to be cost-effective are used frequently and do not require 
promotion, the drugs “on the margins of evidence-based medicine” are prescribed more 
frequently when advertised (Abel 2006). This conclusion has been supported by previous 
studies; in a randomized clinical trial using patient actors, Kravitz and colleagues found that 
DTCA is more influential when drugs are of questionable use (Kravitz et al., 2005).  In the study, 
patients who presented with depression (where an antidepressant is a reasonable choice), general 
requests were more effective than brand-specific requests.  Patients who presented with an 
adjustment disorder (where use of antidepressants is more questionable), brand-specific patient 
requests were more effective.  Another study found that physicians were more likely to prescribe 
a Cox-2 inhibitor if the patient had requested it after seeing the advertisement, even though a 
different drug (non-steroidal anti-inflammatory medication) is the more appropriate choice 
according to the current evidence (Spence, Teleki, Cheetham, Schweitzer, & Millares, 2005).  
2.2.2 DTCA of Cancer Prevention Services  
While pharmaceutical advertising is the most studied form of DTCA, advancements in the field 
of genetics in the past decade have created new products, and as such, new opportunities for 
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cancer-related DTCA.   Many of these products are aimed at cancer detection and secondary 
prevention, which allows for marketing to a much broader target population (Kontos & 
Viswanath, 2011).  Promotion of cancer prevention products includes such services as genetic 
testing, whole-body imaging, and cancer screening and surveillance tests (Abel et al., 2012). 
2.2.3 Genetic Testing 
With the sequencing of the human genome, opportunities for investigating genetic-related cancer 
became possible.  Direct-to-consumer marketing for genomic testing is rapidly increasing, with 
more than 30 websites currently marketing these at-home tests (Genetics & Public Policy Center, 
2010).  In the past few decades, genetic tests have been developed to test for mutations that 
increase susceptibility to cancer, such as the BRCA1 and BRCA2 mutations for breast cancer.  
Other tests include those for single nucleotide polymorphisms that relate to cancer risk, as well 
as for genetic testing of metabolism of pharmaceutical medications (Abel et al., 2012).  
One DTCA campaign was piloted by Myriad Genetics in 2002 in Denver, Colorado and 
Atlanta, Georgia, and then a larger campaign ran in 2007 throughout the Northeastern United 
States (Ray, 2007).  The company currently holds the patent for the BRCA1 and BRCA2 mutation 
test, and holds all genetic testing and advertising privileges. The genetic test advertised by the 
company, called BRACAnalysis®, was promoted through television commercials featuring 
women of various ages and races, attesting the same message: 
 
“Breast cancer runs in my family. My mother, my grandmother, my dad’s sisters. I 
wondered if it would be inevitable. I found out it didn’t have to be. I found out my 
risk through BRACAnalysis®… a blood test that has helped thousands of women 
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find out their risk for hereditary breast and ovarian cancer. After BRACAnalysis®, 
I realized I can choose to do something now, to help reduce my cancer risk now, 
with effective medical options.” 
 
The ad reported that one in ten women have a BRCA1 of BRCA2 mutation, but critics 
argue this number is misleading, and that a woman in the general population has a one in 400 
chance (Genetics & Public Policy Center, 2007).  The media effects of the larger campaign (in 
terms of the number of women purchasing tests and undergoing testing) have not yet been 
published, but the Centers for Disease Control and Prevention conducted a survey of 1,635 
women and 1,054 providers to examine the effects of the pilot (Centers for Disease Control and 
Prevention, 2004).  The study compared outcomes in the two cities with the Myriad Genetics 
campaign (Denver and Atlanta) with two cities without the campaign (Raleigh-Durham and 
Seattle) and found that women were twice as likely to have heard about genetic testing if they 
lived in a city with prevalent advertisements (p<0.05).  In addition, health providers in cities with 
DTCA for genetic tests were twice as likely to report an increase of requests for the genetic tests 
within the past six months (p < 0.05).   
The topic of DTCA for genetic testing has become controversial (S. Gray & Olopade, 
2003).  Public health agencies and physicians have criticized DTCA for cancer-related genetic 
tests (Lowery, Byers, Axell, Ku, & Jacobellis, 2008; Mouchawar, Hensley-Alford, et al., 2005; 
Mouchawar, Laurion, et al., 2005).  Even though genetic testing may be beneficial for high risk 
groups, there is debate as to whether advertising of such services is the appropriate method to 
disseminate such information to the public (Kontos & Viswanath, 2011). One of the major issues 
of DTCA for genetic testing is that it influences members of the population that are not at high 
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risk for developing cancer and increases the need for genetic counseling services among low risk 
groups (Lowery et al., 2008; Mouchawar, Hensley-Alford, et al., 2005; Tracy, 2008).  Other 
concerns include potential patient misunderstanding of test results and the confidentiality of 
genetic information (S. Gray & Olopade, 2003; Lowery et al., 2008; Mouchawar, Hensley-
Alford, et al., 2005; Mouchawar, Laurion, et al., 2005; Tracy, 2008).  
Multiple studies examined the impact of the BRCAnalysis campaign by Myriad Genetics 
and reported that managed care organizations had significant increases in low-risk patients 
getting tested and needing genetic counseling services (Lowery et al., 2008; Mouchawar, 
Hensley-Alford, et al., 2005; Tracy, 2008).  This has raised concerns about unnecessary 
psychological stress on patients who have false positive results and increased health care costs 
for follow-up and counseling services (Hamilton, Lobel, & Moyer, 2009). There is also a 
concern about at-home genetic tests that do not require interaction with a health care provider 
(United States Federal Trade Commission, 2006). A content analysis of these websites found that 
messages about risks of testing are often omitted, and patients may misunderstand the 
information presented (Lachance, Erby, Ford, Allen, & Kaphingst, 2010). The FDA has recently 
banned such website distribution of genetic tests, stating that they are medical devices in need of 
more regulation (Abel et al., 2012).  
2.2.4 Cancer Screening Services 
Just as genetic testing services are advertised to the public, services for cancer screening are also 
highly promoted in the media (Abel et al., 2012).  For over a century, health professionals and 
public health organizations have viewed cancer screening as an effective way to save lives 
(Lerner, 2001).  For decades, cancer-screening ads have utilized persuasion techniques to evoke 
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fear and guilt to promote screening, but even ads with proven benefit have recently received 
scrutiny for failing to mention risks of screening or likelihood of false positive results (Woloshin, 
Schwartz, Black, & Kramer, 2012).  
Many screening services that are not evidenced-based are also promoted through media 
channels. Radiological screening tests, such as whole-body positron emission tomography or 
computed tomography (CT) are marketed by non-academic facilities (Fenton & Deyo, 2003; T. 
H. Lee & Brennan, 2002).  This type of screening test is low in sensitivity and specificity, 
meaning patients’ chances for false positive and false negative results are increased (Illes et al., 
2004; T. H. Lee & Brennan, 2002).  An analysis of advertisements for imaging services found 
that they make unsubstantiated claims, omit risk information, and include financial incentives 
(Illes et al., 2004).  Critics believe that these tests are expensive, unnecessary, and may require 
invasive or costly follow-up tests (Illes et al., 2004; Manning & Schneiderman, 1996).  Screening 
services for cancer-related biomarkers are also advertised to the public; this practice has been 
criticized recently because tests are not evidenced-based and results are difficult to interpret, 
even by experienced oncologists (Viswanath, 2005). 
2.3 ADVERTISING BY CANCER CENTERS 
Advertisements for pharmaceutical medications, genetic testing, and imaging services are clearly 
examples of direct-to-consumer marketing of cancer-related services, and these types of 
advertising have been analyzed to varying degrees.  However, it is also important to recognize 
that facilities that provide cancer care—such as hospitals, clinics, and cancer centers—promote 
their services to patients in order to attract new customers and increase revenue (S. W. Gray & 
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Abel, 2012).  Marketing of health care services and treatments is very competitive, especially in 
larger cities (Rosenthal, 2010).  Despite the recession, hospitals were still placing ads in 2008; 
the total advertising spending by U.S. hospitals increased slightly from $1.2 billion in 2007 to 
$1.23 billion a year later, according to TNS Media Intelligence (Newman Andrew Adam, 2009).  
From January to July 2011, advertising by American hospitals, clinics, and medical centers rose 
20.4 percent, from $595.5 million to $717.2 million during the six-month period, as compared 
with the same period in 2010 (Newman Andrew Adam, 2011).  Hospital and cancer center 
advertising has recently received some attention by the media (Newman Andrew Adam, 2011; 
Oxman, January, 2007; Singer, December 18, 2009), but has yet to receive much evaluation by 
academic researchers in the academy.   
A major concern about advertising by non-profit hospitals and clinics in particular is its 
comparatively lenient regulation.  For-profit centers ads are regulated by the FTC, and must meet 
certain criteria about accuracy of claims; however, the FTC does not regulate ads placed by non-
profit centers.  While hospitals have received some criticism, it seems as though cancer centers 
advertising in particular has raised more serious concerns.  According to a recent article in the 
New York Times entitled, “Cancer Center Ads Use Emotion More Than Facts,” federal agencies 
cannot limit the claims made by non-profit cancer centers about their success in curing cancer, 
even though these statements are often anecdotal and unsubstantiated (Singer, December 18, 
2009). According to the article, even cancer center ads that promote specific services, such as a 
new radiation therapy, do not have to demonstrate effectiveness.  However, the FDA would 
require evidence for such a claim if the device manufacturer had run the advertisement. The FDA 
has strict requirements for risk, benefit, and indication language in pharmaceutical and medical 
device advertisements.   
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The FDA has strict requirements for advertising pharmaceutical and medical-device 
products. Such companies must submit their promotional materials to the FDA at the same time 
(or before) they appear in the lay media.  FDA staff members review the ads, and if violations 
occur may send one of two types of letters:  1) an “untitled letter” that requests the company 
remove the ad, or 2) a “warning letter” that requires the company to pull the ad and run a 
corrective campaign (Abel et al., 2007).  The majority of regulatory letters sent by the FDA from 
1997 to 2006 cited ads for minimizing risks, exaggerating the effectiveness of a medication or 
device, or both (J. M. Donohue et al., 2007).  Although the number of FDA reviewers is severely 
limited (there were only four in 2006), despite the increasing number of ads submitted each year 
(J. M. Donohue et al., 2007), all advertisements from pharmaceutical and medical device 
companies are being examined for compliance.  
A 2010 article in the Oncology Times reports that there is no regulation of non-profit 
hospital (or cancer center) advertising by a federal agency for claims of accuracy (Rosenthal, 
2010).  Lisa M. Schwartz, MD, MS, of Dartmouth Medical School, and co-author of study 
examining advertising by academic medical centers (Larson, Schwartz, Woloshin, & Welch, 
2005) commented, “People are often surprised that this is unregulated advertising, and it can 
generate false hope and unrealistic expectations about treatment. They may assume it falls under 
the FTC but it doesn’t.” Dr. Schwartz noted that some oversight for non-profit center ads may 
come from the each state’s attorney general’s office, but said she was not aware of any corrective 
actions that had taken place.  For-profit cancer centers have received citations from the FTC for 
making false claims about cure, but this oversight does not apply to non-profit cancer centers 
(Federal Trade Comission, 2011; Singer, December 18, 2009).  
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In addition to receiving criticism for lenient regulation, non-profit and for-profit cancer 
center advertising has raised concerns among health professionals and academic investigators for 
the persuasion techniques utilized. Critics note that these ads often make unsupported claims 
about patient survival, highlight atypical patients, omit statistical information about risks and 
benefits, use emotional language, and promote innovative therapies without much scientific 
consensus on the effectiveness of such treatment (Newman Andrew Adam, 2011; Oxman, 
January, 2007; Singer, December 18, 2009). Figure 2 highlights four examples of advertisements 
placed by cancer centers in popular U.S. magazines, obtained from Kantar Media, a media 
monitoring organization (see Appendix for permission to use).  
Critics are also concerned that ads may generate false hope and unrealistic expectations 
about treatment success. While encouraging optimism among patients may produce positive 
outcomes (Federal Trade Comission, 1996; Felder, 2004; Jansen, 2011), high expectations may 
cause distress when a treatment is unaffordable or when its results are disappointing (Tomlinson 
& Wright, 2004).  Unrealistic expectations about treatment benefit may influence patients to 
choose treatment options that do not match their true preferences or values (Temel et al., 2011; 
The, Hak, Koeter, & van Der Wal, 2000; Weeks et al., 1998).  For example, a patient who 
understands and accepts she has a minimal chance of survival from aggressive anti-cancer 
treatments may choose supportive therapies and an improved quality of life in order to enjoy 
hobbies or spend time with friends and families.  Patients with misconceived notions about the 
effectiveness of anti-cancer therapies may be left with regret about their treatment choice after 
they haven’t received the results they expected (The, Hak, Koeter, & van Der Wal, 2000).   
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MD Anderson Cancer Center (top left), Cancer Treatment Centers of America (top right), Memorial Sloan-Kettering Cancer Center 
(bottom left), Stanford Women’s Cancer Center (bottom right), obtained from Kantar Media.  
Figure 1.  Examples of Advertisements Placed By Cancer Centers in 2012, Obtained from Kantar Media 
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Other health professionals have expressed concern that ads may cause unnecessary 
burden on cancer patients by convincing them to spend time and money to travel across the 
country for care that often is available closer to home (Singer, December 18, 2009).  Lastly, 
some have expressed concern about ads increasing health care costs by promoting innovative, 
and sometimes unproven, treatments. Not only does this promote the idea that new treatments are 
always better, it may lead to unnecessary procedures that put patients at risk for additional 
appointments and corrective procedures (Rosenthal, 2010; Singer, December 18, 2009). 
The unregulated (or minimally regulated) nature of both for-profit and non-profit cancer 
center advertising, coupled with the often-unsubstantiated claims present in advertisements have 
created debate as to whether this type of advertising should be more regulated.  A large body of 
evidence regarding the content, impact, and regulation of pharmaceutical advertising has been 
reviewed, with regular updates (Abel et al., 2006; Frosch & Grande, 2010; Kontos & Viswanath, 
2011; Wilkes et al., 2000).  However, to our knowledge, there has not been a rapid review of the 
research examining the content of DTCA by cancer centers.  Characterizing the content of 
messages conveyed through cancer center advertisements is the first step to understanding if and 
how these messages affect patients.  As evidence suggests that pharmaceutical, genetic testing, 
and cancer screening advertisements affect health care costs, patient preferences and 
expectations about benefits of treatments, and the provider-patient relationship, it is of high 
public health importance to assess the effect of other health-services advertisements, especially 
those receiving criticism for advertising campaigns.  To inform the debate, this study aims to 




3.0  METHODS 
3.1 SELECTION CRITERIA 
Studies were included in the review if they examined any form of promotional advertisements 
placed by cancer centers in popular media outlets (broadcast, print, or online). Exclusion criteria 
were created a priori and helped guide whether studies identified by the literature review were 
appropriate for inclusion.  Publications were excluded from the review if they met any of the 
following conditions:  were not published in a peer-reviewed journal, provided a case study of an 
advertising company or mentioned an ad company winning a marketing campaign, assessed 
advertisements placed by hospitals, clinics, or medical centers that did not advertise cancer 
treatments or services, provided only an opinion or comment on other articles about cancer 
center advertising, or were published in a language other than English. 
3.2 SEARCH STRATEGY 
The rapid search was conducted using three databases that archive publications in medicine and 
health, psychology, and business:  MEDLINE (from 1950), PsychInfo (from 1950), and Business 
Source Complete (from 1950). The subject scope of MEDLINE is biomedicine and health, and 
includes publications on topics such as pharmaceutical and health services advertising, health 
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communication, and the impact of advertising on providers and patients.  This database was 
chosen due to its broad coverage of oncology-related and health communication journals.  Psych 
Info contains information in the field of psychology, and includes publications on marketing 
communications, particularly social marketing interventions.  This database was searched due to 
its broad coverage of health communication publications.  Business Source Complete includes 
publications from business and peer-reviewed journals, as well as non-journal content such as 
industry reports, case studies, market research reports, and company profiles.  This database was 
chosen for its broad coverage of marketing campaigns in all fields.   
The databases were searched for all relevant literature (i.e. publications in peer-reviewed 
journals, books, case studies, and reports) published up to February 9, 2013.  The search included 
Medical Subject Headings (MeSH) relating to oncology clinical services, advertising, and 
marketing practices of oncology-related health facilities.  The MeSH terms “marketing,” 
“marketing of health services,” and “advertising as topic” were combined with terms used for 
facilities that provide cancer care, such as “oncology service, hospital,” “cancer care facilities,” 
“outpatient clinics, hospital,” “academic medical centers,” and “ambulatory care facilities.”  The 
terms “cancer center or cancer centers” and “cancer clinics or cancer clinic” were also used as 
related words describing facilities that provide cancer care.  
One researcher conducted the literature search and scanned the title and abstract of the 
studies identified during the preliminary review.  At the point of abstract review, a decision was 
made whether the study fit inclusion criteria.  Full-text copies of potentially eligible studies were 
retrieved for full evaluation if the title and abstract met the inclusion criteria.   
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3.3 DATA EXTRACTION 
Data collected from eligible studies included information on study design and study outcomes.  
Information extracted on study design included distinct units of analysis (i.e. print or television 
advertisements or websites), total number of unique units of analysis, time period studied, 
number of reviewers, and inter-rater reliability between reviewers.  The outcome measures 
included information on the services advertised, the balance of risks and benefits language and 
the quality of study design (as measured by standardized coding, number of reviewers, sampling 
strategy, and unit of analysis representativeness).  The type or themes of promotional claims (in 
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4.0  RESULTS 
4.1 STUDY SELECTION 
Two studies were selected from 353 publications identified by the rapid review (Figure 2).  After 
removal of duplicates, 346 remained.  Preliminary title and abstract review led to the exclusion 
of 336 studies.  Most of the publications that did not fulfill the inclusion criteria were social 
marketing articles, with the majority falling into one of the following categories:  effects of 
tobacco advertising or the impact of tobacco cessation campaigns, advertising of family planning 
prevention campaigns (e.g. oral and skin), or advertising to recruit participants into research or 
intervention studies. Of the articles discussing direct-to-consumer advertising, the majority 
discussed the content of or attitudes toward pharmaceutical advertising.  Among the articles 
related to advertising by cancer care facilities, very few characterized the content or analyzed the 
impact of cancer services advertising.  Twenty-nine were reports of the specific marketing 
campaigns of single cancers or advertising agencies contracted with cancer centers published in 
non-peer-reviewed journals or newspapers.  The majority of these reports were found in the 
publications Profiles of Healthcare Marketing, Modern Healthcare, or Profile of Health 
Communication.  These articles were not included, as they were not published in peer-reviewed 
publications.    
 
 





































Figure 2.  Literature Search and Article Selection 
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evidence to support effectiveness of such treatment (Lau et al., 2008), 2) Korean preferences for 
western or eastern medicine through advertising (Shin et al., 2011), 3) online promotion of 
robotic prostatectomy (Mirkin et al., 2012), and 4) a discussion between a senior oncologist, a 
cancer survivor, an ethicist, and an oncology fellow about pharmaceutical-related direct-to-
consumer advertising (Abel et al., 2006). Three other articles rejected on full review were 
opinion pieces about cancer center advertising (English, Klein, Niehaus, & Ross, 2005; Hunter-
Snow, 2006; Romano, 2005).  As these articles did not systematically analyze advertising 
content or impact, they were not included. One study reported the effectiveness of a single 
hospital campaign (Menon, Goodnight, & Wayne, 2006).  This study was submitted by members 
of the marketing team of the respective hospital and was not published in a peer-reviewed 
journal.   
4.2 CHARACTERISTICS OF STUDIES INCLUDED 
Only two studies were identified that represented evaluations of advertising by facilities that 
provided cancer care (Table 1).  Both were cross-sectional studies conducted in the United 
States.  The Larson, Schwartz, Woloshin, and Welch article entitled, “Advertising by Academic 
Medical Centers” was published in 2005 in the Archives of Internal Medicine.  Investigators 
conducted a content analysis of newspaper advertisements placed by “America’s Best Hospitals” 
(as awarded by U.S. News & World Report) in 2002.  Authors also conducted semi-structured 
interviews with the marketing departments of the 17 medical centers.  
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Table 1.  Characteristics and Main Findings of Studies that Fulfilled Search Criteria 
 
“A Netnographic Exploration, Listening to Online Consumer Conversations,” published 
in the Journal of Advertising Research in 2010 by Rama Jayanti, explored the content of 40 NCI-
designated cancer-center websites and explored consumer conversations on health-related 
electronic bulletin boards.  The purpose of this study was to inform hospital communication 
strategies by examining if patient needs and desires were accounted for in current marketing 
campaigns. The author describes netnography as “adapting ethnographic techniques to the online 
world,” and it involves observing online culture just as an anthropologist would study a 
community (Jayanti, 2010). Using this approach, the author participated in an online consumer 
conversation through a disease-specific electronic bulletin board, immersing herself in 
conversations for over two years. Through stratified sampling, five different threads were 
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For the Larson et al. study, the distinct units of analysis were print advertisements placed 
by the academic medical centers in the top five most widely circulating newspapers in the 
centers’ metropolitan area.  In 2002, investigators identified 122 unique newspaper ads for 
examination.  The units of analysis for the Jayanti study were National Cancer Institute-
designated comprehensive cancer center websites.  Forty were examined for promotional 
content.  
Both studies had two investigators review units of analysis and both assessed reliability.  
The Larson et al. article calculated reliability using a Kappa measure.  Only items with a κ value 
of 0.70 or higher were included in the analyses.  The Jayanti article reports inter-coder agreement 
as 90 percent for marketing themes found on NCI-designated websites, but does not mention 
how this value was determined.  
4.3 STUDY OUTCOMES 
Several types of outcome measures were examined, and the main results are shown in Table 1. 
The Larson article found that of the 127 advertisements reviewed, 65 promoted groups of 
services for a specific condition, among which cancer was the second most common condition 
targeted, after cardiovascular disease.  Twenty-one ads promoted specific treatments or tests, 
with the majority (19/21, 90%) promoting procedures considered cosmetic, e.g. botulinum toxin 
type A (Botox), or experimental, e.g. a total body computed tomographic scan.  The majority of 
these ads used persuasion principles that evoked feelings such as hope or fear, and about one-
third highlighted innovative technology or therapies. The University of Chicago Hospitals, for 
example, advertised an offer for a $25 heart screening under the headline, "Early detection is key 
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to surviving heart disease."  Among these discrete services advertised, more than three-quarters 
highlighted potential benefits, but none quantified the claims.  Only one ad mentioned any 
potential risks of the procedures, and this ad did not describe the risks but only mentioned that 
risks exist.  
Of the 17 interviews with the marketing departments of each respective medical center, 
16 reported using advertising to attract patients. None of the medical centers had the 
advertisements reviewed by an ethics committee, such as the Institutional Review Board, 
although most (66.7%) knew that research ads were required to undergo this type of review. 
About half (8/17) reported that individual departments could create and place their own ads 
(Larson et al., 2005). 
Overall, authors concluded that ads focusing on innovative technology might foster the 
perception that medical care is better than it actually is, leading to false hope and unrealistic 
expectations among patients, and increasing costs for healthcare. In addition, authors mentioned 
that services promoting unproven procedures may expose patients to unnecessary risks. They 
suggested a need for fair balance of benefits and risks and minimization of the promotion of 
services with unclear value.  
The Jayanti study, in which the author participated in an online consumer conversations 
for over two years, identified four themes from the netnographic exploration of patient 
conversations: 1) Provider-consumer partnership, defined as shared decision-making between a 
patient and the provider, with respect for provider clinical expertise and patient preferences for 
treatment, 2) Social vulnerability, or embarrassing changes in a patient’s physical appearance 
caused by the disease, 3) Disease management, defined as patient self-management of disease 
symptoms that providers fail to recognize and treat, and 4) Getting back to normalcy, or patient 
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goal-setting to return to levels of health experienced before the onset of disease.  The author then 
explored the content of cancer-center websites to see if similar themes emerged and better inform 
hospital marketing strategies.   
The content analysis of the 40 NCI-designated comprehensive cancer-center websites 
found that the centers advertise in one of three ways:   
1. By promoting institutional prestige by means of highlighting awards, accolades, and 
reputational strength.  For example (as quoted in Jayanti), “Jonnson Comprehensive 
Cancer Center has established an international reputation in a number of areas, such as 
developing new cancer therapies, providing the best in experimental and traditional 
treatments, and expertly guiding and training the next generation of medical researchers.”  
2. By highlighting expertise and research conducted at the center, e.g., “…home to 
outstanding, internationally recognized physicians and scientists.  These individuals 
collaborate across the full spectrum of cancer research from basic biology to treatment.” 
3. By emphasizing the delivery of compassionate care.  For example, “As it grows to fulfill 
its mission, the Cancer Center will continue to be distinguished by its compassionate and 
effective patient care.”  
 
The author discovered a disconnect between the conversations of patients and the 
marketing messages promoted by cancer centers.  These recommendations from both the 
netnographic and content analyses were delivered to hospital communication managers so that 
more relevant, powerful, and believable messages could be given to consumers.   
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4.4 STUDY QUALITY 
Both studies provided data on the number and consistency of assessors, but only the Larson et al. 
article used a calculated kappa measure. The Jayanti article did not report how inter-coder 
reliability was conducted.  Another limitation of the Jayanti study is the sample timeframe:  it 
reflected the state of the NCI-designated websites at a particular point in time and the time period 
was not reported in the article. Neither study examined the ease of readability of promotional 
material.  A standard measure of readability, such as the Flesch-Kincaid Grade Level formula 
that calculates the reading level required for understanding of the material, would have been a 
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5.0  DISCUSSION  
This report summarizes the review examining DTCA by cancer centers.  Given the discussion 
that has taken place in the lay media (Rosenthal, 2010; Singer, December 18, 2009), it is 
surprising that the content of cancer center advertisements has not been subjected to more 
rigorous evaluation.  This review found only two studies in the peer-reviewed literature that 
explored the topic.  Overall, the results of these studies did not provide enough information to 
make any conclusive statements about the content of cancer center advertising, including the 
services advertised, language usage, or presentation of risks and benefits.  
5.1 SYTHESIS AND LIMITATIONS OF RESULTS 
The Larson et al. article systematically explores the content of advertisements placed by 
academic medical centers, but not cancer centers specifically.   Although cancer centers are often 
branches of hospital and medical centers, it is impossible to deduce if these ads are similar to 
those advertised by cancer centers. This study found that of 65 advertisements for grouped 
services, only ten targeted cancer.  Since the majority of advertisements promoted non-cancer-
related services and treatments, it is unlikely that the findings of the study can be generalized to 
advertising by cancer centers. Furthermore, the Larson et al. article examined advertisements 
from the top 17 academic medical centers, as measured by U.S. News & World Report.  The 
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content of advertisements placed by other, lower-rated centers cannot be determined from this 
study.  In addition, the study only examined newspaper ads.  Other forms of advertising, such as 
magazine, radio, or television, may differ in content. Lastly, the time period studied was January 
to December of 2002, and it is likely that the content of ads of persuasion techniques used has 
changed over the last ten years.   
While the Larson et al. study looked at advertising by academic centers, the Jayanti 
article specifically examined the content of cancer center websites.  However, the author 
examined NCI-designated comprehensive cancer center websites only.  As the NCI designation 
is awarded to the nation’s top cancer centers, the promotional website content of the nation’s 
less-prestigious cancer centers cannot be deduced from this study.    
Another limitation to the Jayanti article is that only website content was analyzed, not 
direct-to-consumer advertising practices by these centers. The methods are also vague and would 
be difficult to reproduce.  The author does not mention a standardized codebook for systematic 
examination of the websites, nor a process of how and which webpages were examined (e.g. the 
home page, mission statement, vision, treatment option, or treatment result sections).  There is 
mention of 90 percent inter-coder agreement, but there is no discussion as to how this value was 
achieved. Lastly, there was no systematic examination of persuasion techniques or balance of 
risk and benefit information.  
5.2 COMMONALITIES BETWEEN STUDIES 
Despite the limitations of study design and study relevance, there were some commonalities 
between the two articles.  Both found that promotional materials (websites and newspaper 
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advertisements) mentioned the center’s prestige, used emotional language, and provided patient 
testimonials.  
5.2.1 Institutional Prestige 
Both studies found that the majority of medical (or cancer) centers promote their image by 
highlighting institutional expertise and awards.  The Larson et al. study found that 60.7% of all 
ads highlighted institutional prestige, defined as, “uses claims of institutional prestige or status 
(‘world renowned,’ ‘top rated,’ ‘expertise,’); cites awards (e.g. US News & World Report 
rating)” (2005).  The Jayanti study reported that 100% of NCI-designated cancer center websites 
had themes of institutional self-promotion (“self-presentation of reputation, awards, and 
accolades,”) and expertise/experience/research (“providing information in numeric form with 
regard to size, number of expert physicians, and budgets”) (2010).   
As these studies both examined promotional material from the top medial centers in the 
U.S., (as determined by the NCI-designation or U.S. News & World Report honor roll mention), 
it is no surprise that these centers highlight their status. It would be interesting to see how other, 
less rated, cancer centers advertise their services.   
5.2.2 Emotional Appeal  
Promotion of institutional prestige is not a concerning finding, especially if the claim is 
warranted.  However, both studies mentioned the use of emotional language in promotional 
material.  Larson et al. found that the majority of ads (61.5%) had “emotional appeal,” defined 
as, “evokes feelings such as hope, fear, anxiety, or sympathy; alludes to important relationships; 
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focuses on health risk, disability, or death” (2005).  The Jayanti article, while not including this 
persuasion technique as a theme, used examples containing emotional language when describing 
other themes, revealing that these persuasion principles are being used, to some degree, by NCI-
designated comprehensive cancer centers (2010).   
The use of emotional language in oncology-related health services advertising has raised 
concerns among many investigators of DTCA (Abel et al., 2006; Kontos & Viswanath, 2011; 
Kravitz & Bell, 2007; Oxman, January, 2007).  Cancer patients and their families, having 
received a cancer diagnosis, are likely afraid, desperate, and vulnerable (Oxman, January, 2007).  
Patients making decisions about medical services may have severe emotional and/or physical 
stress, and they may be especially vulnerable to marketing manipulation (Abel et al., 2006; 
Kontos & Viswanath, 2011).  This vulnerable position should encourage avoidance of marketing 
techniques that use of emotion language (i.e., evoked feelings of hope, fear, happiness, anxiety, 
or sympathy), however, some have observed that the opposite seems to be true (Larson et al., 
2005; Latham, 2004). Despite the concerns, to our knowledge there has been no examination of 
the use of emotional language specifically in cancer center advertisements.  
5.2.3 Patient Testimonials 
The third commonality found among studies was the use of testimonials.  Larson et al. found that 
about six percent of ads promoted services with endorsements by a celebrity, patient, or health 
care provider (2005).  While the Jayanti article did not directly report testimonials as a theme, 
many of the exemplars from hospital websites came from patient stories (2010).  For example, 
the patient theme, “getting back to normalcy” was found in a television commercial highlighting 
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a patient who had undergone surgery and was cured.  In the commercial the patient said, “today I 
live a completely normal life.”   
Although both studies suggest that testimonials are used to advertise, neither article 
mentioned the use of disclaimers.  Testimonials are often used to promote consumer products, 
and the FTC requires the use of disclaimers.  In October 2009, the FTC revised disclaimer 
requirements, mandating not only a disclaimer for testimonial advertisements, but also a 
description of the typical results a consumer might expect (Federal Trade Comission, 2011). The 
FTC found that disclaimers alone (e.g. a statement reading “results not typical”) did little to 
lessen consumers’ expectation of benefit, even when using explicit disclaimers such as, “These 
testimonials are based on the experiences of a few people and you are not likely to have similar 
results” (Federal Trade Comission, 2009).  While the two studies included in the review mention 
the use of disclaimers, it is unknown if hospital advertisements using patient testimonials include 
disclaimers, and if so, comply with the new FTC requirements.   
The use of patient testimonials has raised concerns among health professionals because 
they often highlight miraculous survival stories, which may mislead patients into thinking their 
chances for survival are better than they actually are.  Unrealistic expectations about cure may 
influence patients to make decisions about treatments that do not reflect their true preferences 
and lead to regret (Temel et al., 2011; The et al., 2000; Weeks et al., 1998).   In addition, high 
expectations may cause distress when a treatment is unaffordable or when the outcome is 
disappointing (and in the case of cancer, possibly devastating).  For example, a qualitative study 
of men who used a drug for erectile dysfunction found that expectations raised by advertising 
embellishment had an adverse effect on the morale of those for whom it was ineffective 
(Tomlinson & Wright, 2004).   
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5.3 COMMUNICATION THEORIES  
Mass media communication of health-related topics has attracted the attention of numerous 
health professionals due to its perceived power and influence in shaping human behavior 
(Finnegan & Viswanath, 2008).  The first media-effect research study examined the impact of 
World War II propaganda on soldiers and citizens; more recent studies have examined the impact 
of movies, television, video games, and the Internet on the well-being of children (Finnegan & 
Viswanath, 2008).  Such studies have outlined mechanisms of how media content affects viewer 
behavior.  Three general groups of theories have influenced this work:  1) theories that explain 
the mechanisms that shape behavior, such as Expectancy-Value theories, 2) theories of 
information processing (e.g. deliberately and consciously vs. peripherally), and 3) message-effect 
theories (e.g. using techniques such as framing or narratives) (Finnegan & Viswanath, 2008).  
5.3.1 Expectancy-Value Theories 
Expectancy-value and message-effect theories are the most relevant to the examination of cancer 
center advertising. These theories have been applied extensively in psychology in many areas, 
including learning theories, attitude theories, and decision-making theories (Edwards, 1954; 
Rosenberg, 1956; Rotter, 1954). The fundamental assumption of Expectancy-Value theories is 
that people’s behavioral choices are driven by the beliefs or expectancies they have about 
outcomes of their choices, as well as the value they place on those outcomes.  New information 
from advertising messages may either modify patients’ beliefs or reinforce their existing beliefs.   
Health center advertising campaigns, as is evident from the Larson and Javanti article, use 
persuasion techniques that shape a patients’ belief about expectation, such as patient survival 
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testimonials, use of language about survival, and institutional reputation about curing disease.  
As evidenced from expectancy-value theories, a person’s expectation of a particular outcome (in 
this case successful cancer treatment or cure), strongly affects behavior.  This may be 
particularly worrisome if advertisements promote false or misleading claims about survival or 
cure, as a patient is making a decision based on his or her expectation of benefits (which, in this 
case, may be inaccurate).  
5.3.2 Media-Effect Theories 
Media or message effect theories assume that the format and delivery of messages interact with 
the audience members’ attitudes and beliefs (Capella & Rimer, 2006). Multiple elements 
comprise media effect theories (e.g., framing, exemplification, and sensation seeking), but the 
element of exemplification is particularly relevant to health-services advertising.   
Exemplars in health communication messages are descriptive individual cases that are 
“less valid but more vivid” (Brosius, 1994).  Testimonials fall into the category of exemplars, as 
they provide an illustrative example of a general class of events.  For example, an advertisement 
about a woman who has successfully undergone a new type of treatment for breast cancer would 
serve as an exemplar for others who are considering the treatment.  Some research has shown 
that exemplars are more effective when they use emotional language (Zillmann, 2006). The 
Larson article found that the majority of ads used emotional language (evoked feelings of hope, 
fear, happiness, anxiety, or sympathy).  This indicates that this persuasion technique, if coupled 
with exemplars, is likely effective.   In addition, research has shown that audience members who 
identify and empathize with the character will become more susceptible to the persuasive 
message (Finnegan & Viswanath, 2008). 
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5.4 RESEARCH PRIORITIES 
This review has noted several gaps in research that have not been adequately investigated.  
Firstly, only one study has examined the advertising content of medical centers, and this content 
analysis was not specific to cancer center advertising (Larson et al., 2005).  One study examined 
cancer center websites, but not any form of DTC advertisements (Jayanti, 2010).  Descriptive 
studies examining the content of print and broadcast advertising of cancer centers should be 
prioritized, given the increase of hospital advertising and the concern expressed in the lay media 
(Oxman, January, 2007; Rosenthal, 2010; Singer, December 18, 2009). A recent study that 
synthesized updates in direct-to-consumer marketing (DTCM) in oncology supported this notion, 
suggesting that, “rigorous health services research methods must be used to explore the content 
of DTCM,” (Abel et al., 2012).   
Descriptive studies should systematically describe the content of cancer center 
advertisements with particular attention to the types of services advertised (and the clinical 
evidence supporting such therapies), the balance of information about risks and benefits (and use 
of statistics), and the frequency of testimonial disclaimers that comply with FTC requirements. 
The use of persuasion techniques should also be explored, with attention to language that evokes 
hope, fear, or anxiety, suggests survival or medical miracles, focuses on innovation or treatment 
advances, mentions institutional prestige or experience, or uses patient survival testimonials.  
Since research on DTCA for pharmaceutical medications has shown that the information 
presented is often difficult to read and requires a high level of literacy and numeracy (Kaphingst 
et al., 2004, 2005), research on the ease of readability of cancer center ads would provide useful 
information and could achieved by using a standard measure of readability, such as the Flesch-
Kincaid Grade Level formula.  
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These studies would provide a foundation for research on the implications of cancer 
center advertising on patient preferences for and expectations about benefit from certain 
treatments and therapies.  Studies assessing if and how such ads affect patients emotionally could 
be conducted, as well as those measuring the effect of advertising on the patient-provider 
relationship.  Studies could also measure how advertisements influence patterns of patient travel 
and expenditure on cancer care and treatment.  Such impact studies would then inform policy 
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6.0  CONCLUSION 
6.1 STUDY LIMITATIONS  
This review has several limitations.  First, this study was a rapid review conducted over a two-
month period.  Whereas a traditional systematic review can take 12 months or more to conduct, 
rapid reviews synthesize evidence over a shortened timeframe.  It is possible that studies meeting 
the inclusion criteria were not retrieved through the search strategy, as only three databases were 
searched.  As only one person conducted the review, it is also possible that studies meeting 
criteria were mistakenly excluded during preliminary reviews.  Publication bias may also be 
present due to the shortened timeframe for searching and article retrieval.  However, comparison 
with other literature in the field, such as a review of oncology-related DTCM (Abel et al., 2012), 
indicates that this study has not failed to identify relevant articles.  Furthermore, analysis of the 
references of studies included did not identify any additional articles meeting inclusion criteria.   
Second, the number of studies is too small and their methods and quality too variable to 
allow for confident conclusions about the content of cancer center advertising.  The units of 
analysis examined (cancer center websites and academic medical center newspaper ads) are not 
representative of all cancer centers or all forms of DTCA.  As a result, the findings of this review 
cannot be generalized to all cancer center advertisements.  
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Third, this review was limited to articles that were published in English.  Excluding 
studies written in other languages may have led to the exclusion of publications that analyzed the 
content of cancer center advertising in other countries.  However, it is unlikely this study missed 
content analyses in other languages, as the U.S. and New Zealand (both English-speaking 
countries) are the only nations that permit DTCA for health-related products (Kravitz & Bell, 
2007). 
6.2 PUBLIC HEALTH RELEVANCE 
Describing the content of advertising messages conveyed through cancer center advertisements 
is the first step to understanding if and how these communications affect the population.  It is 
evident that communication of health-related messages through the media influences human 
behavior (C. F. Parvanta, 2011); social marketing techniques have been used successfully to 
inform and persuade the public when health practices and products have proven health benefits 
and scientific consensus (C. F. Parvanta, 2011).  However, other forms of health-related 
messages, such as DTCA promoted by companies selling their products and services, have less 
benefit to the public, yet still influence behavior.  In fact, evidence suggests that pharmaceutical 
advertising has no clear public health benefit (i.e., has not shown improved health outcomes or 
improved communication), and yet has the potential to adversely affect health care costs, patient 
expectations about benefits of treatments, and the relationship between doctors and patients 
(Kontos & Viswanath, 2011).  As such, it is of high public health importance to assess the effects 
of other health-services advertisements, including those placed by cancer centers, as these ads 
target a segment of the population that may be particularly vulnerable to marketing manipulation.  
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6.3  FINAL REMARKS  
The liberalization of federal regulatory efforts, increase in information availability 
through technological innovation, and a movement towards a participatory patient involvement 
in medical decision-making has increased DTCA of health-related products. With economic 
pressures and competition growing, cancer centers will continue to advertise their facilities as a 
means to increase revenue, and the value of DTCA will continue to be debated.  This review 
found only two studies that explored the topic, and both had considerable limitations.  While the 
number of studies found was too small and their methods and quality too variable to allow for 
any confident conclusions to be made, this study identified a considerable gap in the literature.  
More research on the content of cancer center advertising needs to be conducted to 
inform the debate, and more light needs to be shed on the effects of the millions of dollars 
advertisers spend annually. Descriptive studies of the content of cancer center advertising are 
needed to move the debate forward and inform studies measuring the impact on the public.  
Understanding the messages conveyed through cancer center advertisements and their effect on 
the population are of high public health importance, as such messages likely influence the 
public’s expectancies of benefits from cancer treatment.  Some advertising of cancer services 
may indeed be necessary, but it should not threaten informed patient decision-making or cause 
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